Author

M. H. Diallo

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Multiregion profiling of genomic and transcriptional heterogeneity in head and neck squamous-cell carcinoma

Background Intratumoral heterogeneity (ITH) is thought to contribute to tumour evolution and treatment resistance but its biological and clinical significance in localised head and neck squamous-cell carcinoma (HNSCC) remains incompletely understood. Patients and methods In the prospective SCANDARE study, we analysed 8...

V. Heurtier, G. Marret, C. Lamy et al. · ESMO Open · 0 citations

Open access Sep 2026

Efficacy and safety of pembrolizumab-lenvatinib in metastatic endometrial cancer: results from the French multicenter early access program.

BACKGROUND Pembrolizumab-lenvatinib (P/L) is a standard option for patients with advanced or metastatic endometrial cancer (a/m EC) progressing after platinum-based chemotherapy, based on the KEYNOTE-775 trial. However, concerns remain regarding its real-world applicability, particularly in older, frailer patients and...

D. B. Roufai, L. Mansi, M. H. Diallo et al. · ESMO Open · 0 citations

Open access Aug 2026

Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort

Background Extensive-disease small-cell lung cancer (ED-SCLC) is an aggressive disease with limited effective therapeutic options. Clinical trials suggest an additive effect of chemotherapy and immunotherapy in SCLC, although the magnitude of benefit seems to be limited. Considering the prolonged peripheral persistence...

E. Gobbini, M. H. Diallo, C. Clément-Duchêne et al. · ESMO Open · 0 citations